Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study

References

• Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–S31. doi:10.1038/onc.2009.198
   PubMedGoogle Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/s1470-2045(11)70393-x
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589. doi:10.1016/s1470-2045(16)30033-x
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. doi:10.1016/s1470-2045(17)30608-3
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi:10.1056/NEJMoa1411817
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662
   PubMed Web of Science ®Google Scholar
• Eide IJZ, Helland Å, Ekman S, et al. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer. 2020;143:27–35. doi:10.1016/j.lungcan.2020.03.009
   PubMed Web of Science ®Google Scholar
• Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013;31(8):1070–1080. doi:10.1200/jco.2012.43.3912
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.Ccr-12-2246
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang S, Zhang B, et al. Clinical factors affecting the response to osimertinib in non-small cell lung cancer patients with an acquired epidermal growth factor receptor T790M mutation: a long-term survival analysis. Target Oncol. 2020;15(3):337–345. doi:10.1007/s11523-020-00724-y
   PubMed Web of Science ®Google Scholar
• Kato Y, Hosomi Y, Watanabe K, et al. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2019;11(6):2350–2360. doi:10.21037/jtd.2019.06.03
   PubMed Web of Science ®Google Scholar
• Ono T, Igawa S, Ozawa T, et al. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: a prospective observational study. Thorac Cancer. 2019;10(4):880–889. doi:10.1111/1759-7714.13018
   PubMed Web of Science ®Google Scholar
• Lee MJ, Weng CM, Chao W, et al. Platelet activation in high D-dimer plasma plays a role in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with mutant lung adenocarcinoma. Front Oncol. 2022;12:876051. doi:10.3389/fonc.2022.876051
   PubMed Web of Science ®Google Scholar
• Peng D, Shan D, Dai C, et al. Real-world data on osimertinib in Chinese patients with pretreated, EGFR T790M mutation positive, advanced non-small cell lung cancer: a retrospective study. Cancer Manag Res. 2021;13:2033–2039. doi:10.2147/cmar.S287466
   PubMed Web of Science ®Google Scholar
• Ma M, Cao R, Wang W, et al. The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and meta-analysis. J Cardiothorac Surg. 2021;16(1):243. doi:10.1186/s13019-021-01618-4
   PubMed Web of Science ®Google Scholar
• Park JY, Jang SH, Lee CY, et al. Pretreatment neutrophil-to-lymphocyte ratio and smoking history as prognostic factors in advanced non-small cell lung cancer patients treated with osimertinib. Tuberc Respir Dis. 2022;85(2):155–164. doi:10.4046/trd.2021.0139
   PubMed Web of Science ®Google Scholar
• Zhang M, Wu S, Hu C. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. J Int Med Res. 2020;48(1):300060519896919. doi:10.1177/0300060519896919
   PubMed Web of Science ®Google Scholar
• Ma Y, Li G, Li X, et al. Clinical characteristics and prognostic analysis of Lung Cancer patients with Hypercoagulability: a single-center, retrospective, real-world study. J Cancer. 2021;12(10):2968–2974. doi:10.7150/jca.46600
   PubMed Web of Science ®Google Scholar
• Hammouda A, Souilah S, Ferhat-Hamida MY, Amir ZC, Aouichat-Bouguerra S, Hariti G. Activation de la coagulation chez des patients atteints du cancer du poumon [Activation of coagulation in patients with lung cancer]. Ann Biol Clin. 2019;77(3):272–280. French. doi:10.1684/abc.2019.1445
   PubMed Web of Science ®Google Scholar
• Chen C, Li J, Li J, et al. Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer. Ann Transl Med. 2020;8(18):1153. doi:10.21037/atm-20-5947
   PubMed Web of Science ®Google Scholar
• Li X, Lu D, Zhang Z, Zhang Y, Wang J, Hu Y. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study. J Thorac Dis. 2022;14(10):4125–4135. doi:10.21037/jtd-22-1363
   PubMed Web of Science ®Google Scholar
• Guo J, Gao Y, Gong Z, et al. Plasma D-Dimer level correlates with age, metastasis, recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) patients. Biomed Res Int. 2021;2021:9623571. doi:10.1155/2021/9623571
   PubMed Web of Science ®Google Scholar
• Chang F, Zhang H, Chen C, et al. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small-cell lung cancer. Future Oncol. 2022;18(6):679–690. doi:10.2217/fon-2021-0455
   PubMed Web of Science ®Google Scholar
• Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):773–775. doi:10.1038/bjc.1993.140
   PubMed Web of Science ®Google Scholar
• Giordano M, Boldrini L, Servadio A, et al. Differential microRNA expression profiles between young and old lung adenocarcinoma patients. Am J Transl Res. 2018;10(3):892–900.
   PubMed Web of Science ®Google Scholar